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CASE PRESENTATION
A 71-year-old African-American female was admitted to
the hospital with hemoptysis, interstitial pneumonia,
pleural and pericardial effusions, and mediastinal
lymphadenopathy. There was a history of hypertension
and chronic kidney disease, but her serum creatinine had
been relatively stable at 1.6 mg/100 ml (141 mmol/l) for
the past year. She was treated initially with ethambutol
and azithromycin for possible mycobacterium avium
intracellulare, but these were subsequently discontinued
when no definite mycobacteria were identified on lung
biopsy. She also received linezolid for possible
staphylococcal pneumonia. Bronchoscopic biopsy and
examinations of pleural and pericardial fluid were
nondiagnostic. During her hospital course, she developed
cardiac arrhythmia and was treated with amiodarone. She
was discharged 3 weeks after admission with a diagnosis
of interstitial pneumonia of unclear etiology. Her serum
creatinine at discharge was 2.4 mg/100 ml (212 mmol/l),
but over the next 4 months, it slowly increased to
3.5 mg/100 ml (309 mmol/l). She was re-admitted for
further evaluation.
Past medical history was significant for hypertension,
positive antinuclear antibody (first detected before
hydralazine treatment), positive tuberculin skin test,
hemoptysis, interstitial lung disease and mediastinal
lymphadenopathy from unclear etiologies, hypertrophic
cardiomyopathy, mitral regurgitation, and aortic
insufficiency. Home medications included amiodarone,
calcium acetate, iron, furosemide, potassium, hydralazine,
prednisone, pantoprazole, sodium bicarbonate, clonidine,
glargine insulin, and nifedipine.
During questioning, it was discovered that the patient
had been mistakenly taking a high dose of amiodarone
(200 mg three times a day) for the past 4 months. The
dosage was decreased to 200 mg/day and subsequently
discontinued a few days later. Family history was
remarkable for a deceased brother with end stage renal
disease presumed to be due to diabetic nephropathy.
Review of systems was significant for dyspnea, but
otherwise was negative for burning sensation in her
extremities, chronic abdominal pain, stroke, skin rash,
or foamy urine.
On admission, her physical examination revealed an
obese female with a blood pressure of 162/76 mm Hg
and a heart rate of 76. She was afebrile. There was a
systolic murmur, but the rest of the examination was
unremarkable. Specifically, there was no evidence of
angiokeratoma, bluish-gray skin discoloration, or
neurological abnormality. Laboratory values are illustrated
in Table 1. Her perinuclear anti-neutrophil cytoplasmic
antibody was positive at 32 a.u./ml (normal o19 a.u./ml),
and an antinuclear antibody was positive at 1:160
(homogeneous). She underwent diagnostic renal biopsy.
RENAL BIOPSY FINDINGS
There were six glomeruli in the sections for light microscopy.
Two were globally sclerotic, and the remaining glomeruli
showed segmental mildly increased mesangial matrix with
mild mesangial hypercellularity. Some of the capillary lumina
were dilated and filled with vacuolated cells (Figure 1).
No vacuolation was identified in the visceral epithelial cells
with the periodic acid-Schiff hematoxylin and silver stains.
There was patchy mild interstitial fibrosis. Some of the
tubules were quite dilated and contained hyaline casts. There
was no significant interstitial inflammation. The arterioles
were unremarkable. One medium-sized artery at the
corticomedullary junction showed moderate intimal fibrous
thickening.
Sections for immunofluorescence contained four glomeruli.
There was no staining for IgG, IgM, IgA, C1q, C3, albumin or
light chains in the glomeruli, vessels, or tubular basement
membranes.
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Examination of the semi-thin sections by light microscopy
revealed small inclusions in visceral epithelial and mesangial
cells, as well as occasional proximal tubular epithelial cells.
No inclusions were noted in parietal epithelial or endothelial
cells. Ultrastructural examination of two glomeruli revealed
mildly increased mesangial matrix. The capillary base-
ment membranes showed moderate thickening due to
widening of the lamina densa as well as focal expansion of
the subendothelial space. In some capillary loops, the
subendothelial zone was lucent and contained fluffy material.
Many glomerular capillaries were occluded by vacuolated
cells (Figure 2). The foot processes were focally effaced.
Numerous lamellated lipid inclusions (‘myeloid bodies’)
were noted, primarily in visceral epithelial cells, but also
occasionally in mesangial cells and tubular epithelial cells
(Figure 3a). No inclusions were identified in endothelial cells.
The biopsy was interpreted as showing features suggestive
of Fabry disease, with superimposed mild interstitial fibrosis
and moderate arteriosclerosis.
CLINICAL FOLLOW-UP
In light of the kidney biopsy findings in association with her
underlying cardiac disease and positive family history of renal
disease, an assay for plasma a-galactosidase A was performed
at Mt. Sinai School of Medicine. The plasma a-galactosidase
A level was low at 2.2 U/ml (normal range 6.2–18.6 U/ml).
Figure 1 | Glomerulus with dilated capillary lumina containing
vacuolated cells. No vacuolization of the visceral epithelial cells is
evident. There is mildly increased mesangial matrix with
mesangial hypercellularity. (Periodic acid-Schiff hematoxylin;
original magnification  400).
Figure 2 | Capillary lumen occluded by vacuolated histiocytes.
Note the lamellated inclusions in the visceral epithelial cell
(original magnification  20,000).
Figure 3 | Comparison of ultrastructural findings in
amiodarone-induced phospholipidosis and Fabry disease.
(a) Electron micrograph showing enlarged visceral epithelial cells
with numerous large lipid inclusions. The capillary wall is mildly
thickened, and there is focal effacement of the foot processes
(original magnification  12,600). (b) Lipid inclusions in
visceral epithelial cells from a patient who has Fabry disease.
Note that inclusions may be relatively sparse (original
magnification  12,600).
Table 1 | Laboratory values
Serum/blood (reference range)
Blood urea nitrogen (mg/100 ml) 62 (7–17)
Creatinine (mg/100 ml) 3.5 (0.7–1.2)
Urine (reference range)
Urinalysis pH 7, specific gravity 1.014, 30 mg
protein/100 ml
Microscopy 5–20 white blood cells/high power
field
1–4 red blood cells/high power field
No casts
Serologic tests (reference range)
Antinuclear antibody 1:160 (negative)
Anti-neutrophil cytoplasmic
antibody myeloperoxidase
32 a.u./ml (o19 a.u./ml)
Serine protease3 8 a.u./ml (o20 a.u./ml)
C3 135.7 mg/100 ml (90–180)
C4 24 mg/100 ml (16–38)
DNA antibody Negative
Hepatitis B antigen Nonreactive
HCV Nonreactive
Aspartate aminotransferase 737 (14–36 U/l)
Alanine aminotransferase 584 (9–52 U/l)
Rheumatoid factor 16 IU/ml (o10 IU/ml)
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Assay of leukocyte a-galactosidase A was not performed.
Subsequently, DNA sequencing for mutations in the
a-galactosidase gene was also performed at Mt. Sinai School
of Medicine. No mutation was identified in the coding
regions or adjacent intron/exon boundaries of the patient’s
a-galactosidase gene. Independent slit-lamp examination
by two ophthalmologists revealed cornea verticillata, which
are golden-brown or gray opacities that branch out from a
central whorl, usually across the inferior cornea (Figure 4).
This finding supports a diagnosis of systemic lipidosis, but
it does not differentiate Fabry disease from drug-induced
phospholipidosis.
Because of the negative a-galactosidase gene mutation
studies and lack of explanation for the cause of the relatively
sudden decline in her renal function, we explored alternative
explanations for renal phospholipidosis. Gentamycin, chloro-
quine, and hydroxychloroquine are cationic amphiphilic
drugs that have been reported as causes of drug-induced
phospholipidosis with renal biopsy findings similar to those
in Fabry disease,1–4 but the patient had never received any of
those medications. However, amiodarone is also a cationic
amphiphilic drug, and it is well known to cause lamellated
phospholipid inclusions in lung biopsies from patients with
amiodarone pulmonary toxicity.5 Moreover, amiodarone and
other cationic amphiphilic drugs are known to cause cornea
verticillata indistinguishable from that of Fabry disease.6
Therefore, we suspected that amiodarone was the cause of her
phospholipidosis.
As there are data showing that antioxidants such as
silymarin and vitamin E may reduce lysosomal phospho-
lipidosis in amiodarone toxicity in animals,7 she was
empirically placed on vitamin E treatment. Following dis-
continuation of amiodarone, her creatinine slowly decreased.
Her serum creatinine 2 and 3 months after discontinuation of
amiodarone declined to 2.7 (239 mmol/l) and 2.4 mg/100 ml
(212 mmol/l), respectively. Repeat measurement of her
plasma a-galactosidase A level 3 months after discontinua-
tion of amiodarone was 0.148 U/l (normal range
0.016–0.200 U/l; performed by ARUP Laboratories, Salt Lake
City, UT, USA). It is worth noting that her aspartate
aminotransferase and alanine aminotransferase were also
elevated on admission and gradually improved after the
withdrawal of amiodarone. These abnormal values probably
represented amiodarone hepatotoxicity, although liver biopsy
was not performed. In retrospect, the patient’s positive
perinuclear anti-neutrophil cytoplasmic antibody may have
been secondary to treatment with hydralazine. The final
diagnosis was amiodarone-associated renal and corneal
phospholipidosis mimicking Fabry disease.
DISCUSSION
Intracellular phospholipid accumulation as concentric lamel-
lar bodies (zebra bodies or myelin figures) in kidney biopsy
specimens is a well-recognized finding in Fabry disease,
which is an X-linked lysosomal storage disorder secondary
to a-galactosidase A deficiency, resulting in accumulation
of glycosphingolipids (particularly globotriaosylceramide)
in various tissues. However, phospholipidosis can also
be induced by cationic amphiphilic drugs, which are
compounds that contain an aromatic or aliphatic ring
structure and a hydrophilic region that is positively charged
at physiologic pH.8 For example, gentamycin has long been
known to cause ‘myelin bodies’ in kidney biopsy specimens
that are similar to those of Fabry disease, although in the case
of gentamycin toxicity, the deposits are confined to tubular
epithelium. Hydroxychloroquine and chloroquine, which
are potent inhibitors of lysosomal phospholipase A and C,
are additional examples of amphiphilic drugs that cause
lamellated phospholipid inclusions in kidneys mimicking
Fabry disease.1–4 As noted above, amiodarone is also a
cationic amphiphilic drug, and its ability to produce similar
inclusions in various tissues is not surprising. However,
although it is a well-known cause of pulmonary and hepatic
toxicity, significant renal toxicity has not been described. In
particular, there have not been any previous reports of myelin
bodies in amiodarone-induced nephrotoxicity in humans.
Electron microscopic studies in amiodarone-induced
pulmonary toxicity have shown lamellated phospholipid
inclusions similar to those observed in Fabry disease.9 On the
other hand, the occlusion of glomerular capillary lumina by
vacuolated histiocytes in our patient is not typical of Fabry
disease. Similar findings were noted by Albay et al.1 in a
patient with chloroquine-induced lipidosis, and they sug-
gested that they might be a distinguishing feature unique
to chloroquine cell injury. Mu¨ller-Ho¨cker et al.2 did not
mention these changes in their report of a patient with
chloroquine toxicity, but one of the figures in their paper
shows a capillary luminal cell with similar features. In
conjunction with the findings in our case, it is reasonable to
suggest that this abnormality is a common feature of cationic
amphiphilic drugs. However, it should be mentioned that
Bracamonte et al.3 specifically noted that such histiocytes
were not present in their case of hydroxychloroquine renal
toxicity, nor did Woywodt et al.4 mention this finding.
There are several mechanisms by which cationic amphi-
philic drugs induce phospholipidosis, and they may not be
exactly the same for each drug. In general, these drugs inhibit
the activity of lysosomal phospholipases, resulting in the
Figure 4 | Verticillata on the right inferior cornea.
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accumulation of one or more classes of phospholipids in
lysosomes.8 This inhibition may occur when cationic
amphiphilic drugs bind to hydrophobic and hydrophilic
moieties of phospholipids, resulting in complexes that are
undigestible by lysosomal phospholipases.8 However, there is
also evidence that cationic amphiphilic drugs directly inhibit
lysosomal phospholipases. Studies in an in vitro cell culture
model showed inhibition of phospholipases A1 and A2
by amiodarone, which prevented lysosomal phospholipid
degradation and thus led to accumulation in various cell
types.10 Similarly, chloroquine is known to inhibit a number
of lysosomal phospholipases.11,12
On the basis of the above observations, the decrease in
a-galactosidase A level in our patient noted just after the
biopsy was performed is probably not surprising. In vitro
studies of chloroquine have shown a specific inhibitory
action on a-galactosidase activity.13 Although a specific effect
on a-galactosidase A has not been shown for amiodarone, it
is certainly not unreasonable to expect that it might occur.
As the patient’s plasma a-galactosidase A level returned to
the normal range within several months after stopping
amiodarone therapy, we suspect that the temporary decrease
was secondary to amiodarone toxicity.
Lipidosis-inducing drugs such as amiodarone, chloro-
quine, amodiaquine, benoquin, tilorone, and gentamycin
may also cause intraepithelial corneal deposits in a verticillate
pattern (cornea verticillata) similar to Fabry disease.14,15
However, in only one of the reports of renal toxicity
associated with hydroxychloroquine or chloroquine were
corneal lesions described.4 In one case report of chloroquine
toxicity, there is no specific mention of corneal involvement,
but the authors state that no clinical features of Fabry disease
were identified.1 In the other two reports, the authors
specifically state that there was no corneal involvement.2,3 On
the other hand, corneal involvement in patients who are
taking amiodarone appears to be quite common. In one
study, 35 of 37 patients who were taking amiodarone
developed cornea verticillata.15 Cornea verticillata have been
shown to be reversible after discontinuation of amiodarone.15
In our patient, follow-up ophthalmologic examination
performed 4 months after discontinuation of amiodarone
showed improvement but persistence of cornea verticillata.
Induction of lipidosis by cationic amphiphilic drugs is dose
dependent, and discontinuation of these drugs can lead to
reversal of phospholipidosis.8 However, in humans, there is a
paucity of data on the rate of reversal. In one case report of
hydroxychloroquine renal toxicity, the primary renal abnorm-
ality was increasing proteinuria with only mild elevation of
the serum creatinine.3 Six months after the renal biopsy,
proteinuria had improved slightly (decreasing from a high of
3.38 g/24 h to 2.16 g/24 h), and serum creatinine had returned
to baseline levels. In the other report of hydroxychloroquine
toxicity, the patient presented with new-onset proteinuria,
and 15 months after renal biopsy, her proteinuria still ranged
between 1.8 and 5 g/day.4 In the two cases of chloroquine
toxicity,1,2 parameters of renal function had recovered to
pretreatment levels after 9 and 12 months. In our patient, the
serum creatinine has declined from a high of 3.5 mg/100 ml
(309 mmol/l) to 2 mg/100 ml (176 mmol/l) 5 months after
discontinuation. This is still 25% higher than her baseline
level before amiodarone therapy, but based on the length of
recovery time for the patients with hydroxychloroquine or
chloroquine toxicity, it is possible that additional recovery of
renal function will occur with longer follow-up.
In summary, phospholipidosis can be induced by a
number of cationic amphiphilic drugs, including amiodar-
one, which cause renal and corneal morphological findings
mimicking Fabry disease. A high index of suspicion is
warranted if a renal biopsy is suggestive of Fabry disease,
because these patients and their family members may benefit
from enzyme replacement therapy.16 As the genetic and
iatrogenic conditions cannot be distinguished on morpho-
logical criteria alone, the diagnosis must be confirmed by
measurement of enzymatic activity and/or mutational
analysis of the a-galactosidase A gene.
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